Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $56.56 which represents a slight increase of $0.50 or 0.89% from the prior close of $56.06. The stock opened at $56.07 and ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

Short BMY slightly under 59.95, target 53.71, stop loss @ 60.12 Check the time stamp on this data. Updated AI-Generated ...

The increases are to list prices, which do not include rebates to pharmacy benefit managers and other discounts.

The healthcare sector has long been a sanctuary for income investors seeking stability and growth. Within this realm, Bristol ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bristol-Myers ...

Halozyme's attempt to acquire Evotec was a bold move to diversify revenue, but was ultimately unsuccessful, impacting HALO's ...

Bristol-Myers Squibb became profitable within the last five years. On the other hand, it reported a trailing twelve months ...

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) yesterday and set a price target of ...

Halozyme (HALO) announced that Bristol Myers Squibb (BMY) received FDA approval for Opdivo Qvantig co-formulated with Halozyme’s Enhanze drug ...